Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach.

Qin Q, Ajewole VB, Sheu TG, Donohue R, Singh M.

Ecancermedicalscience. 2018 May 3;12:832. doi: 10.3332/ecancer.2018.832. eCollection 2018.

2.

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

Marjuki H, Mishin VP, Sleeman K, Okomo-Adhiambo M, Sheu TG, Guo L, Xu X, Gubareva LV.

Antimicrob Agents Chemother. 2013 Nov;57(11):5209-15. doi: 10.1128/AAC.01086-13. Epub 2013 Aug 5.

3.

Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.

Okomo-Adhiambo M, Sheu TG, Gubareva LV.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:44-9. doi: 10.1111/irv.12051. Review.

4.

A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility--North Carolina and South Carolina, 2010-2011.

Garg S, Moore Z, Lee N, McKenna J, Bishop A, Fleischauer A, Springs CB, Nguyen HT, Sheu TG, Sleeman K, Finelli L, Gubareva L, Fry AM.

J Infect Dis. 2013 Mar 15;207(6):966-73. doi: 10.1093/infdis/jis776. Epub 2012 Dec 13.

PMID:
23242536
5.

Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.

Nguyen HT, Trujillo AA, Sheu TG, Levine M, Mishin VP, Shaw M, Ades EW, Klimov AI, Fry AM, Gubareva LV.

Antiviral Res. 2012 Mar;93(3):381-6. doi: 10.1016/j.antiviral.2012.01.006. Epub 2012 Feb 7.

PMID:
22330888
6.

Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11.

Sleeman K, Sheu TG, Moore Z, Kilpatrick S, Garg S, Fry AM, Gubareva LV.

Emerg Infect Dis. 2011 Nov;17(11):2043-6. doi: 10.3201/eid1711.110787.

7.

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV.

Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13. Erratum in: Viruses. 2011 Aug;3(8):1415-6.

8.

Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing.

Levine M, Sheu TG, Gubareva LV, Mishin VP.

J Clin Microbiol. 2011 Apr;49(4):1307-12. doi: 10.1128/JCM.02424-10. Epub 2011 Feb 9.

9.

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.

Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.

Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.

PMID:
21149922
10.

Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010.

Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, Bullion L, Peebles PJ, Li Y, Klimov AI, Gubareva LV.

J Infect Dis. 2011 Jan 1;203(1):13-7. doi: 10.1093/infdis/jiq005.

11.

Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.

Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 Sep;54(9):3671-7. doi: 10.1128/AAC.00581-10. Epub 2010 Jun 28.

12.

Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.

Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 May;54(5):1834-41. doi: 10.1128/AAC.01608-09. Epub 2010 Mar 1.

13.

Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.

Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 Mar;54(3):1102-10. doi: 10.1128/AAC.01417-09. Epub 2009 Dec 22.

14.

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.

PMID:
19917319
15.

Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.

Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):354-60. doi: 10.1016/j.antiviral.2009.10.022. Epub 2009 Nov 1.

PMID:
19887086
16.

Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.

Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, Dharan N, Klimov AI, Gubareva LV.

Antiviral Res. 2009 Jan;81(1):16-24. doi: 10.1016/j.antiviral.2008.08.008. Epub 2008 Oct 7.

PMID:
18835410
17.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.

Supplemental Content

Support Center